# OnCo record ros1-fusion (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/ros1-fusion/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "ros1-fusion" ;
  schema:name "ROS1 fusion (ROS1-positive)"@en ;
  schema:alternateName "ROS1 fusion"@en, "ROS1 rearrangement"@en, "ROS1-positive"@en, "ROS1+"@en, "CD74-ROS1"@en, "CD74::ROS1"@en ;
  schema:description "A ROS1 fusion drives about 1 to 2 percent of lung adenocarcinomas and behaves much like ALK. Crizotinib, entrectinib, repotrectinib and taletrectinib are approved for it."@en ;
  schema:url <https://onco.cc/biomarkers/ros1-fusion/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7c71b0c-2549-4495-86b6-c2807fa54908>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51ac8e52-3269-4102-8dc8-dba22d82128c> ;
  onco:tag "biomarker", "fusion" ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/>, <https://onco.cc/biomarkers/ntrk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/taletrectinib/>, <https://onco.cc/drugs/oncomine-dx-target-test/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/tki-term/> .